IDH1 mutations occur in a small share of acute myeloid leukemia and block normal blood cell maturation. Rezlidhia (olutasidenib) added a second targeted option for these patients.
Olutasidenib inhibits the mutant IDH1 enzyme, lowering the oncometabolite 2-hydroxyglutarate so immature leukemia cells can resume normal differentiation. The twice-daily capsule treats adults with relapsed or refractory acute myeloid leukemia carrying a susceptible IDH1 mutation detected by an approved test.
Rezlidhia carries a boxed warning for differentiation syndrome, an on-target effect of restored maturation that requires prompt recognition. It holds orphan designation and competes directly with ivosidenib, making tolerability and hepatic safety the practical differentiators.
